|
1
|
Anderson WF, Jatoi I, Tse J and Rosenberg
PS: Male breast cancer: A population-based comparison with female
breast cancer. J Clin Oncol. 28:232–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mabuchi K, Bross DS and Kessler II: Risk
factors for male breast cancer. J Natl Cancer Inst. 74:371–375.
1985.PubMed/NCBI
|
|
3
|
Ewertz M, Holmberg L, Tretli S, Pedersen
BV and Kristensen A: Risk factors for male breast cancer-a
case-control study from Scandinavia. Acta Oncol. 40:467–471. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NCCN: Genetic/Familial High-Risk
Assessment: Breast and Ovarian Cancer. 2015.http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdfAccessed.
January 1–2016
|
|
5
|
Müller AC, Gani C, Rehm HM, Eckert F,
Bamberg M, Hehr T and Weinmann M: Are there biologic differences
between male and female breast cancer explaining inferior outcome
of men despite equal stage and treatment?! Strahlenther Onkol.
188:782–787. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu XF, Yang HJ, Yu Y, Zou DH and Miao LL:
A prognostic analysis of male breast cancer (MBC) compared with
post-menopausal female breast cancer (FBC). PLoS One.
10:e01366702015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cardoso F, Bartlett J and Slaets L:
Abstract S6-05: Characterization of male breast cancer: First
results of the EORTC10085/TBCRC/BIG/NABCG International Male BC
Program. Cancer Res. 75:S6–05. 2015. View Article : Google Scholar
|
|
8
|
Sobin LH, Gospodarowicz MK and Wittekind
C: The TNM Classification of Malignant Tumours (7th).
Wiley-Blackwell. Geneva: 2009.
|
|
9
|
Diba CS: Cancer incidence in the Slovak
Republic. National Health Information Center. Bratislava:
2009.http://www.nczisk.sk/Documents/publikacie/analyticke/incidencia_zhubnych_nadorov_2009.pdfAccessed.
January 2–2016
|
|
10
|
Shaaban AM, Ball GR, Brannan RA, Cserni G,
Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones
JL, et al: A comparative biomarker study of 514 matched cases of
male and female breast cancer reveals gender-specific biological
differences. Breast Cancer Res Treat. 133:949–958. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leone JP, Leone J, Zwenger AO, Iturbe J,
Vallejo CT and Leone BA: Prognostic significance of tumor subtypes
in male breast cancer: A population-based study. Breast Cancer Res
Treat. 152:601–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Senkus E, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S and Cardoso
F: ESMO Guidelines Committee: Primary breast cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26(Suppl 5): v8–v30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradley KL, Tyldesley S, Speers CH, Woods
R and Villa D: Contemporary systemic therapy for male breast
cancer. Clin Breast Cancer. 14:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Partridge AH, Rumble RB, Carey LA, Come
SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D,
et al: Chemotherapy and targeted therapy for women with human
epidermal growth factor receptor 2-negative (or unknown) advanced
breast cancer: American Society of Clinical Oncology Clinical
Practice Guideline. J Clin Oncol. 32:3307–3329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasano H and Harada N: Intratumoral
aromatase in human breast, endometrial and ovarian malignancies.
Endocr Rev. 19:593–607. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Ronde W and de Jong FH: Aromatase
inhibitors in men: Effects and therapeutic options. Reprod Biol
Endocrinol. 9:932011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nordman IC and Dalley DN: Breast cancer in
men: Should aromatase inhibitors become first-line hormonal
treatment? Breast J. 14:562–569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doyen J, Italiano A, Largillier R, Ferrero
JM, Fontana X and Thyss A: Aromatase inhibition in male breast
cancer patients: Biological and clinical implications. Ann Oncol.
21:1243–1245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bighin C, Lunardi G, Del Mastro L, Marroni
P, Taveggia P, Levaggi A, Giraudi S and Pronzato P: Estrone
sulphate, FSH and testosterone levels in two male breast cancer
patients treated with aromatase inhibitors. Oncologist.
15:1270–1272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zagouri F, Sergentanis TN, Azim HA Jr,
Chrysikos D, Dimopoulos MA and Psaltopoulou T: Aromatase inhibitors
in male breast cancer: A pooled analysis. Breast Cancer Res Treat.
151:141–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Clinical trials: S0511, goserelin and
anastrozole in treating men with recurrent or metastatic breast
cancer. https://clinicaltrials.gov/ct2/show/NCT00217659Accessed.
January 25–2016
|
|
22
|
Di Lauro L, Pizzuti L, Barba M, Sergi D,
Sperduti I, Mottolese M, Amoreo CA, Belli F, Vici P, Speirs V, et
al: Role of gonadotropin-releasing hormone analogues in metastatic
male breast cancer: Results from a pooled analysis. J Hematol
Oncol. 8:532015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Korde LA, Zujewski JA, Kamin L, Giordano
S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh
J, et al: Multidisciplinary meeting on male breast cancer: Summary
and research recommendations. J Clin Oncol. 28:2114–2122. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Ieso PB, Potter AE, Le H, Luke C and
Gowda RV: Male breast cancer: A 30-year experience in south
Australia. Asia Pac J Clin Oncol. 8:187–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iorfida M, Bagnardi V, Rotmensz N, Munzone
E, Bonanni B, Viale G, Pruneri G, Mazza M, Cardillo A, Veronesi P,
et al: Outcome of male breast cancer: A matched single-institution
series. Clin Breast Cancer. 14:371–377. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masci G, Caruso M, Caruso F, Salvini P,
Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M,
Torrisi R, et al: Clinicopathological and immunohistochemical
characteristics in male breast cancer: A retrospective case series.
Oncologist. 20:586–592. 2015. View Article : Google Scholar : PubMed/NCBI
|
